Skip to main content
Top
Published in: Breast Cancer Research 1/2003

Open Access 01-02-2003 | Research article

Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?

Authors: Anna Maria Granato, Oriana Nanni, Fabio Falcini, Secondo Folli, Gabriella Mosconi, Franca De Paola, Laura Medri, Dino Amadori, Annalisa Volpi

Published in: Breast Cancer Research | Issue 1/2003

Login to get access

Abstract

Introduction

The aim of the present study was to analyze the relationship between the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in breast cancer cells and the corresponding serum levels in individual patients. The study also evaluated the potential of serum levels of the two growth factors as diagnostic markers in a case–control study.

Methods

VEGF expression and bFGF expression were determined in 62 and 63 tumor samples, respectively. Serum VEGF and bFGF levels were determined in 54 and 65 healthy women and in 69 and 73 breast cancer patients, respectively, using a quantitative sandwich enzyme immunoassay technique.

Results

A direct correlation was observed between VEGF expression and bFGF expression in individual tumors (P = 0.001) and between serum levels (P = 0.038) in individual patients, but not between tumor cell expression and the corresponding serum level for either growth factor. Median values of serum levels in healthy women and breast cancer patients were not different for VEGF (P = 0.055), but were significantly different for bFGF (P < 0.001). The receiver operating characteristic curve identified a serum bFGF concentration of 1.0 pg/ml, with 84.9% sensitivity and 63.1% specificity, as the best cut-off value to discriminate between healthy women and breast cancer patients. An age-based subgroup analysis showed that serum values of patients older than 70 years of age mainly contributed to the high accuracy.

Conclusions

Our data repropose bFGF as a noninvasive diagnostic tool for breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Folkman J: Clinical application of research on angiogenesis. N Engl J Med. 1995, 333: 1757-1763. 10.1056/NEJM199512283332608.CrossRefPubMed Folkman J: Clinical application of research on angiogenesis. N Engl J Med. 1995, 333: 1757-1763. 10.1056/NEJM199512283332608.CrossRefPubMed
2.
go back to reference D'Amore PA: Heparin–endothelial cell interactions. Haemostasis. 1990, Suppl 1: 159-165. D'Amore PA: Heparin–endothelial cell interactions. Haemostasis. 1990, Suppl 1: 159-165.
3.
go back to reference Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z: Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990, 9: 203-226.CrossRefPubMed Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z: Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990, 9: 203-226.CrossRefPubMed
4.
go back to reference Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994, 86: 356-361.CrossRefPubMed Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994, 86: 356-361.CrossRefPubMed
5.
go back to reference Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996, 2: 821-826.PubMed Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996, 2: 821-826.PubMed
6.
go back to reference Takei Y, M Kurobe, A Uchida, K Hayash: Serum concentrations of basic fibroblast growth factor in breast cancer [letter to the editor]. Clin Chem. 1994, 40: 1980-1981.PubMed Takei Y, M Kurobe, A Uchida, K Hayash: Serum concentrations of basic fibroblast growth factor in breast cancer [letter to the editor]. Clin Chem. 1994, 40: 1980-1981.PubMed
7.
go back to reference Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ: Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res. 2001, 7: 3491-3494.PubMed Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ: Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res. 2001, 7: 3491-3494.PubMed
8.
go back to reference Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and non-malignant disease. Cancer. 1999, 85: 178-187. 10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.3.CO;2-Z.CrossRefPubMed Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and non-malignant disease. Cancer. 1999, 85: 178-187. 10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.3.CO;2-Z.CrossRefPubMed
9.
go back to reference Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H: Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat. 1999, 53: 161-166. 10.1023/A:1006178517505.CrossRefPubMed Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H: Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat. 1999, 53: 161-166. 10.1023/A:1006178517505.CrossRefPubMed
10.
go back to reference Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997, 3: 647-651.PubMed Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997, 3: 647-651.PubMed
11.
go back to reference Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL: Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res. 2000, 20: 1189-1194.PubMed Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL: Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res. 2000, 20: 1189-1194.PubMed
12.
go back to reference Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997, 76: 238-243.CrossRefPubMedPubMedCentral Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997, 76: 238-243.CrossRefPubMedPubMedCentral
13.
go back to reference Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C: Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995, 15: 2675-2677.PubMed Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C: Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995, 15: 2675-2677.PubMed
14.
go back to reference Findeisen R, Albrecht S, Richter B, Deutschmann K, Zimmermann T, Distler W: Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer. Luminescence. 2000, 15: 283-289. 10.1002/1522-7243(200009/10)15:5<283::AID-BIO593>3.3.CO;2-6.CrossRefPubMed Findeisen R, Albrecht S, Richter B, Deutschmann K, Zimmermann T, Distler W: Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer. Luminescence. 2000, 15: 283-289. 10.1002/1522-7243(200009/10)15:5<283::AID-BIO593>3.3.CO;2-6.CrossRefPubMed
15.
go back to reference Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000, 60: 2898-2905.PubMed Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000, 60: 2898-2905.PubMed
16.
go back to reference Emilio A, Aranega A, Sevilla M, Parra G, Villarreal V, Viñas J, Alonso L, Ruiz I, Ribelles N, Gonzalez F: Evolution of serum angiogenic growth factor levels after breast cancer surgery [abstract]. ASCO Proc. 2000, 19: 601- Emilio A, Aranega A, Sevilla M, Parra G, Villarreal V, Viñas J, Alonso L, Ruiz I, Ribelles N, Gonzalez F: Evolution of serum angiogenic growth factor levels after breast cancer surgery [abstract]. ASCO Proc. 2000, 19: 601-
17.
go back to reference Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997, 3: 2187-2190.PubMed Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997, 3: 2187-2190.PubMed
18.
go back to reference Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond). 1998, 94: 395-404.CrossRef Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond). 1998, 94: 395-404.CrossRef
19.
go back to reference Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998, 77: 956-964.CrossRefPubMedPubMedCentral Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998, 77: 956-964.CrossRefPubMedPubMedCentral
20.
go back to reference Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer. 1999, 80: 892-897. 10.1038/sj.bjc.6690437.CrossRefPubMedPubMedCentral Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer. 1999, 80: 892-897. 10.1038/sj.bjc.6690437.CrossRefPubMedPubMedCentral
21.
go back to reference Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood. 1993, 81: 631-638.PubMed Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood. 1993, 81: 631-638.PubMed
22.
go back to reference Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 1995, 36: 193-204.CrossRefPubMed Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 1995, 36: 193-204.CrossRefPubMed
23.
go back to reference Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W: Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002, 198: 1-5.CrossRefPubMed Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W: Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002, 198: 1-5.CrossRefPubMed
24.
go back to reference Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD: Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol. 1995, 8: 665-670.PubMed Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD: Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol. 1995, 8: 665-670.PubMed
25.
go back to reference Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL: Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999, 10: 707-713. 10.1023/A:1008303614441.CrossRefPubMed Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL: Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999, 10: 707-713. 10.1023/A:1008303614441.CrossRefPubMed
26.
go back to reference De Paola F, Granato AM, Scarpi E, Monti F, Medri L, Bianchi S, Amadori D, Volpi A: Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer. 2002, 98: 228-233. 10.1002/ijc.10118.CrossRefPubMed De Paola F, Granato AM, Scarpi E, Monti F, Medri L, Bianchi S, Amadori D, Volpi A: Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer. 2002, 98: 228-233. 10.1002/ijc.10118.CrossRefPubMed
27.
go back to reference Hsiung R, Zhu W, Klein G, Qin W, Rosenberg A, Park P, Rosato E, Sauter E: High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J. 2002, 8: 303-310.CrossRefPubMed Hsiung R, Zhu W, Klein G, Qin W, Rosenberg A, Park P, Rosato E, Sauter E: High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J. 2002, 8: 303-310.CrossRefPubMed
28.
go back to reference Dreisbach L, Cowgill A, Brunn E, Vahedian M, Villar H, Reichlin S, Stopeck A: Random pre-operative VEGF levels are not diagnostic of the presence of breast cancer [abstract]. ASCO Proc. 2000, 19: 2587- Dreisbach L, Cowgill A, Brunn E, Vahedian M, Villar H, Reichlin S, Stopeck A: Random pre-operative VEGF levels are not diagnostic of the presence of breast cancer [abstract]. ASCO Proc. 2000, 19: 2587-
29.
go back to reference Liu Y, Wang JL, Chang H, Barsky SH, Nguyen M: Breast-cancer diagnosis with nipple fluid bFGF [letter]. Lancet. 2000, 356: 567-10.1016/S0140-6736(00)02587-3.CrossRefPubMed Liu Y, Wang JL, Chang H, Barsky SH, Nguyen M: Breast-cancer diagnosis with nipple fluid bFGF [letter]. Lancet. 2000, 356: 567-10.1016/S0140-6736(00)02587-3.CrossRefPubMed
30.
go back to reference Chung HC, Rha SY, Ahn JB, Shim KY, Yoo NC, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ: Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med. 1998, 2: 465-470.PubMed Chung HC, Rha SY, Ahn JB, Shim KY, Yoo NC, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ: Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med. 1998, 2: 465-470.PubMed
31.
go back to reference Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998, 80: 171-175.PubMed Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998, 80: 171-175.PubMed
32.
go back to reference Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 1997, 94: 663-668. 10.1073/pnas.94.2.663.CrossRefPubMedPubMedCentral Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 1997, 94: 663-668. 10.1073/pnas.94.2.663.CrossRefPubMedPubMedCentral
33.
go back to reference Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, Gion M: Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers. 2001, 16: 87-96.PubMed Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, Gion M: Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers. 2001, 16: 87-96.PubMed
34.
go back to reference Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, for the American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19: 1865-1878.PubMed Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, for the American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19: 1865-1878.PubMed
Metadata
Title
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
Authors
Anna Maria Granato
Oriana Nanni
Fabio Falcini
Secondo Folli
Gabriella Mosconi
Franca De Paola
Laura Medri
Dino Amadori
Annalisa Volpi
Publication date
01-02-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr745

Other articles of this Issue 1/2003

Breast Cancer Research 1/2003 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine